April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Dark-Adapted Flash Sensitivity Remains Stable Up to 2 Years After ArgusTM II Implantation
Author Affiliations & Notes
  • G. Dagnelie
    Ophthalmology, Johns Hopkins Univ, Baltimore, Maryland
  • A. K. Ahuja
    Second Sight Medical Products, Inc., Sylmar, California
  • M. J. McMahon
    Second Sight Medical Products, Inc., Sylmar, California
  • A. V. Cideciyan
    Dept of Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania
  • K. G. Locke
    Retina Foundation of Southwest, Dallas, Texas
  • R. J. Greenberg
    Second Sight Medical Products, Inc., Sylmar, California
  • Footnotes
    Commercial Relationships  G. Dagnelie, SSMP, F; A.K. Ahuja, SSMP, E; M.J. McMahon, SSMP, E; A.V. Cideciyan, SSMP, F; K.G. Locke, SSMP, F; R.J. Greenberg, SSMP, E; SSMP, P.
  • Footnotes
    Support  Second Sight Medical Products, Inc
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3029. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Dagnelie, A. K. Ahuja, M. J. McMahon, A. V. Cideciyan, K. G. Locke, Argus II Study Group, R. J. Greenberg; Dark-Adapted Flash Sensitivity Remains Stable Up to 2 Years After ArgusTM II Implantation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3029.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To examine the effects of the ArgusTM II retinal implant on remaining native vision in patients with end-stage retinitis pigmentosa.

Methods: : Using a full-field stimulus test (FST; Roman et al., Exp Eye Res 2005) further developed by Diagnosys (Lowell, MA) for the Espion ColorDomeTM, dark-adapted flash thresholds were collected monocularly in patients with end-stage RP and an Argus II implant in the worse-seeing eye. The test uses a forced-choice yes-no decision paradigm and a modified staircase algorithm to collect probability of seeing data as a function of flash brightness, with the 0 dB point set to 3 cd.s/m². Of 8 patients tested pre-operatively and followed post-operatively at 3 US sites, 6 had pre-op flash thresholds well below the brightness ceiling of the equipment in both eyes. Up to three follow-up measures in each eye were obtained at 3, 6, 9, 12, 18, and 24 months post-op. Thresholds were estimated as the mid-point of the psychometric function.

Results: : Psychometric fits to thresholds above 0 dB had wide confidence intervals in some instances; while others diverged due to gradual light adaptation caused by repeated bright flashes. For those tests where thresholds were near or below 0 dB, average within-session threshold variability was 1.4 (range 0.7,2.4) dB in the implanted eye, 1.4 (range 0.5,2.8) dB in the fellow eye. Both within- and between-visit variability increase with mean threshold level, even for threshold levels below 0 dB. For the patients with at least 3 post-op tests, thresholds in implanted and fellow eyes changed by similar amounts between pre-op levels and the most recent values: Implanted eyes changed on average by +2.5 (range -0.7,6.1) dB, fellow eyes by 0.6 (range -4, +6.1) dB; both changes are within the 95% within-session confidence interval. Moreover, implanted and fellow eyes in individual patients tended to fluctuate in conjunction from session to session suggesting systemic rather than eye-specific variability

Conclusions: : Using dark-adapted flash thresholds as a measure of residual native vision we conclude that, on average, implanted eyes fare no worse than fellow eyes, supporting the notion that the presence and activity of the Argus II implant has no harmful effect on remaining photoreceptor function in these late-stage RP patients.

Clinical Trial: : www.clinicaltrials.gov NCT00407602

Keywords: retinal degenerations: hereditary • low vision • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.